BioSpace News Archive

WELL Health Technologies Corp. is pleased to announce that Hamed Shahbazi, Chairman and CEO, will be participating in the CIBC Western Institutional Investor Conference.

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common Share”) for the month of January 2023, which is payable on February 15, 2023 to shareholders of record at the close of business on January 31, 2023.

Acurx Pharmaceuticals, Inc. is pleased to announce that it has been invited to present at the Emerging Growth Conference on January 25, 2023.

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that Professor Ramon Varcoe will present 12-month data from the SWING Trial, a first-in-human study of the safety and performance of the Sundance™ Sirolimus Drug-Coated Balloon (DCB).

Sirona Biochem Corp. announces the termination of the Rodan + Fields agreement for supply and use of TFC-1067 in commercial formulations.

PetDx® – The Liquid Biopsy Company for Pets™ has released a white paper demonstrating that OncoK9®, its pioneering multi-cancer early detection test for dogs, can enhance cancer monitoring in canine patients with a simple blood draw.

The Barbara Ann Karmanos Cancer Institute kicks off year two of its “Inspired” campaign, inviting the community to view a cancer diagnosis not as an ending but as an opportunity to think bigger, think broader, think “Cancer is a Beginning.”

XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO’s conference call regarding the presentation of the Report on operations 2022.

American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRF) (the “Company” or “Aires”) announces that, further to its previous press releases of May 9, 2022, June 23, 2022, August 2, 2022, August 26, 2022, September 21, 2022, October 21, 2022, November 3, 2022 and December 6, 2022,

OBiO Technology (Shanghai) Corp., Ltd. (‘OBiO’, 688238.SH), a gene and cell therapy-focused contract research organization (CRO) and contract development and manufacturing organization (CDMO), recently announced that the United States Food and Drug Administration (FDA) has accepted its GMP plasmid DNA drug master file (DMF), DMF Number 037766.